EEG and ANI Guided Anesthesia and Quality of Recovery

Sponsor
Gangnam Severance Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05936671
Collaborator
(none)
126
1
2
23.8
5.3

Study Details

Study Description

Brief Summary

This study aims to assess whether electroencephalogram (EEG) and nociception level-guided anesthesia can improve quality of recovery after laparoscopic gynecological surgery compared with standard care. Patients will be randomly assigned to either EEG and Analgesia Nociception Index (ANI)-guided anesthesia group (EEG-and-ANI-Guided group) or usual care group (control group). Primary outcome is 15-item Quality of Recovery (QoR-15) score at postoperative day (POD) 1. Secondary outcomes included remifentanil consumption during anesthesia, occurrence of awareness with recall, incidence of undesirable intraoperative movement, emergence time, postoperative pain scores, quality of recovery score at POD 2, and length of hospital stay.

Condition or Disease Intervention/Treatment Phase
  • Procedure: EEG-and-ANI-guided anesthesia
  • Procedure: standard anesthesia
  • Drug: Sevoflurane and remifentanil
  • Device: EEG and ANI
N/A

Detailed Description

Adult women scheduled to undergo laparoscopic gynecologic surgery will be screened for eligibility. Patients will be randomly allocate to either the EEG-and-ANI-guided group or usual care group.

In the guided group, sevoflurane concentration will be titrated according to EEG monitoring. Intraoperative infusion of remifentanil will be titrated by ANI monitoring.

In the usual care group, EEG and ANI sensor will be attached to patients, but EEG and ANI monitor will be blinded to the attending anesthesiologists. The anesthesiologists will provide a standard care of our institution for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the anesthetic depth and analgesic dose.

Blinded investigator will assess quality of recovery questionnaire-15 at postoperative day 1 and 2.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, single-blinded, parallel-group, randomized clinical studyProspective, single-blinded, parallel-group, randomized clinical study
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Patients, medical staff who measure outcome variables, surgeons and nurses in the recovery room and wards are blinded so that medical staff and patients do not know the patient's assigned group.
Primary Purpose:
Treatment
Official Title:
Quality of Recovery After Electroencephalogram and Nociception Level-guided Versus Standard Anesthesia Care in Female Patients Undergoing Laparoscopic Gynecological Surgery: A Randomized Controlled Trial
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jun 19, 2025
Anticipated Study Completion Date :
Jun 25, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: EEG-and-ANI-guided group

During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.

Procedure: EEG-and-ANI-guided anesthesia
During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.

Drug: Sevoflurane and remifentanil
For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.

Device: EEG and ANI
EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.

Active Comparator: Usual care group

During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.

Procedure: standard anesthesia
During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.

Drug: Sevoflurane and remifentanil
For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.

Outcome Measures

Primary Outcome Measures

  1. 15-item Quality of Recovery (QoR-15) at postoperative day (POD) #1 [24 hours after the end of surgery]

    The Korean version of 15-item Quality of Recovery (QoR-15) score. Each item uses an 11-point numeric rating scale. The sum of the scores of the 15 items ranges from 0 to 150, with a high score indicating good quality of recovery.

Secondary Outcome Measures

  1. Remifentanil consumption during anesthesia [During surgery, from the anesthetic induction to emergence of anesthesia]

    Total remifentanil consumption during anesthesia

  2. Occurrence of awareness with recall [During the operation.]

    Occurrence of awareness with recall during surgery, which will be asked at postoperative day #1.

  3. Incidence of undesirable intraoperative movement [During the operation.]

    Incidence of undesirable intraoperative movement during surgery

  4. Intraoperative end-tidal sevoflurane minimum alveolar concentration (MAC) [During the operation]

    Intraoperative end-tidal sevoflurane minimum alveolar concentration (MAC)

  5. Intraoperative time ANI <50 [%] [During the operation.]

    Intraoperative time of ANI value <50 / total duration of surgery (%)

  6. Intraoperative mean PSi [During the operation.]

    Intraoperative mean Patient state index (a processed EEG parameter related to a patient's current level of sedation/anesthesia along a scale of 0 to 100, where 100 represents being fully awake)

  7. Intraoperative mean ANI [During the operation.]

    Intraoperative mean Analgesia Nociception Index (expressed on a non-unit scale of 0-100; 100 indicates maximal relative parasympathetic tone)

  8. Intraoperative EEG burst suppression [During the operation]

    Intraoperative occurrence of burst suppression on electroencephalogram

  9. burst suppression ratio [During the operation]

    Intraoperative burst suppression ratio on electroencephalogram

  10. burst suppression duration [During the operation]

    duration of burst suppression on electroencephalogram

  11. Emergence time [From time of administration of reversal agents of neuromuscular block until time of extubation, assessed up to 2 hours]

    time between reversal of neuromuscular block and extubation

  12. Intraoperative hypotension [During the operation]

    Incidence of hypotension during surgery

  13. Intraoperative phenylephrine consumption [During the operation.]

    total dose of phenylephrine consumption during surgery

  14. Pain numeric rating scale (NRS) [scores during post-anesthesia care unit (PACU) stay, at postoperative 24, 48 hours]

    NRS (0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable ") pain scores during post-anesthesia care unit (PACU) stay, at postoperative 24, 48 hours

  15. The incidence of post-operative nausea and vomiting [during the post-anesthesia care unit (PACU) stay, at postoperative day 1, 2]

    The incidence of post-operative nausea and vomiting

  16. Patient satisfaction with anesthetic management [At post-operative 24 hours]

    Patient satisfaction with overall anesthetic management in 11-point scale (0-10), The higher the score, the higher the patient's satisfaction.

  17. Quality of Recovery Questionnaire (15-item Quality of Recovery) at postoperative day #2 [At post-operative 48 hours]

    Each item uses an 11-point numeric rating scale. The sum of the scores of the 15 items ranges from 0 to 150, with a high score indicating good quality of recovery.

  18. shivering, airway obstruction, respiratory depression, sedation in PACU [from time of the post-anesthesia care unit (PACU) admission to time of discharge from PACU, assessed up to 2 hours]

    Incidence of shivering, airway obstruction, respiratory depression, sedation

  19. Hospital length of stay [From date of hospital admission until the date of hospital discharge, assessed up to 100 weeks]

    Hospital length of stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Adult female patients who are scheduled to undergo laparoscopic gynecological surgery.

  1. Total laparoscopic hysterectomy with/without salpingo-oophorectomy

  2. Laparoscopic myomectomy

  3. Laparoscope-guided salpingo-oophorectomy

  4. Laparoscope-guided ovarian cystectomy

  5. Laparoscope-guided enucleation of ovarian cyst

Exclusion Criteria:
  1. Patients with nonregular sinus cardiac rhythm

  2. Patients with implanted pacemakers

  3. Patients on antimuscarinic agents, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic agents

  4. pregnant or breastfeeding women

  5. Patients who are unable to communicate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gangnam Severance Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Gangnam Severance Hospital

Investigators

  • Principal Investigator: Dong Woo Han, MD,PhD, Gangnam Severance Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dong Woo Han, Professor, Gangnam Severance Hospital
ClinicalTrials.gov Identifier:
NCT05936671
Other Study ID Numbers:
  • 3-2023-0116
First Posted:
Jul 10, 2023
Last Update Posted:
Jul 10, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 10, 2023